ROS-Responsive Bola-Lipid Nanoparticles as a Codelivery System for Gene/Photodynamic Combination Therapy.
Rui-Mo ZhaoQin-Fang ZhangXiao-Li TianJia-Jia ChenXiao-Qi YuJi ZhangPublished in: Molecular pharmaceutics (2024)
The nonviral delivery systems that combine genes with photosensitizers for multimodal tumor gene/photodynamic therapy (PDT) have attracted much attention. In this study, a series of ROS-sensitive cationic bola-lipids were applied for the gene/photosensitizer codelivery. Zn-DPA was introduced as a cationic headgroup to enhance DNA binding, while the hydrophobic linking chains may facilitate the formation of lipid nanoparticles (LNP) and the encapsulation of photosensitizer Ce6. The length of the hydrophobic chain played an important role in the gene transfection process, and 14-TDZn containing the longest chains showed better DNA condensation, gene transfection, and cellular uptake. 14-TDZn LNPs could well load photosensitizer Ce6 to form 14-TDC without a loss of gene delivery efficiency. 14-TDC was used for codelivery of p53 and Ce6 to achieve enhanced therapeutic effects on the tumor cell proliferation inhibition and apoptosis. Results showed that the codelivery system was more effective in the inhibition of tumor cell proliferation than individual p53 or Ce6 monotherapy. Mechanism studies showed that the production of ROS after Ce6 irradiation could increase the accumulation of p53 protein in tumor cells, thereby promoting caspase-3 activation and inducing apoptosis, indicating some synergistic effect. These results demonstrated that 14-TDC may serve as a promising nanocarrier for gene/PDT combination therapy.
Keyphrases
- photodynamic therapy
- combination therapy
- genome wide
- genome wide identification
- cell death
- cell proliferation
- copy number
- fluorescence imaging
- transcription factor
- oxidative stress
- reactive oxygen species
- dna damage
- genome wide analysis
- randomized controlled trial
- drug delivery
- energy transfer
- cell cycle
- gene expression
- small molecule
- dna methylation
- risk assessment
- heavy metals
- open label
- circulating tumor
- study protocol